Valneva (NASDAQ:VALN) Downgraded by The Goldman Sachs Group to “Neutral”

Valneva (NASDAQ:VALNGet Rating) was downgraded by stock analysts at The Goldman Sachs Group from a “buy” rating to a “neutral” rating in a report issued on Friday, The Fly reports.

Several other equities analysts also recently weighed in on the company. HC Wainwright reduced their target price on Valneva from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Friday, August 19th. Kepler Capital Markets downgraded Valneva from a “buy” rating to a “hold” rating in a report on Thursday, July 28th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. According to, the stock has a consensus rating of “Hold” and an average price target of $35.50.

Valneva Trading Down 6.0 %

Shares of VALN stock opened at $11.66 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.16 and a debt-to-equity ratio of 0.72. Valneva has a 1-year low of $11.46 and a 1-year high of $67.84. The business’s fifty day moving average price is $18.61 and its 200 day moving average price is $24.48.

Valneva (NASDAQ:VALNGet Rating) last posted its earnings results on Thursday, August 11th. The company reported ($2.86) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($1.54). The business had revenue of $76.05 million during the quarter, compared to the consensus estimate of $21.26 million. On average, sell-side analysts anticipate that Valneva will post -1.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. UBS Group AG bought a new stake in Valneva during the 2nd quarter valued at $31,000. Jane Street Group LLC lifted its position in shares of Valneva by 85.9% in the first quarter. Jane Street Group LLC now owns 16,584 shares of the company’s stock worth $569,000 after buying an additional 7,664 shares during the last quarter. Finally, Bank of America Corp DE acquired a new position in shares of Valneva during the 1st quarter worth about $858,000. Institutional investors and hedge funds own 16.39% of the company’s stock.

About Valneva

(Get Rating)

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2.

Further Reading

The Fly logo

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with's FREE daily email newsletter.